Fig. 1.
Study design. DU dulaglutide, GLP-1 glucagon-like peptide-1, LV30 post-study therapy safety follow-up visit, Met metformin, RA receptor agonist, SU sulfonylurea
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.